{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0"}]}],"title":"Atezolizumab SC is much more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0"}]}],"title":"Atezolizumab SC is a little more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0"}]}],"title":"Both formulations are equally convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0"}]}],"title":"Atezolizumab IV is a little more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0"}]}],"title":"Atezolizumab IV is much more convenient"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 2 is being reported here: Question 2: Which formulation of atezolizumab (SC or IV) do you think is more convenient for you? Responses to this question are reported in the data table. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'first participant in \\[FPI\\]' date to 'last participant last visit \\[LPLV\\]' for Part 2).","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, or atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the IV or SC formulations completed the HCP SC versus IV Perspective Questionnaire.","id":"OG000","title":"Part 2: Atezolizumab IV/Atezolizumab SC"}],"paramType":"NUMBER","populationDescription":"Overall number analyzed included HCPs who completed Question 2 of the questionnaire.","reportingStatus":"POSTED","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)","title":"Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire","type":"SECONDARY","unitOfMeasure":"percentage of HCPs"}